<SEC-DOCUMENT>0001193125-14-359767.txt : 20141001
<SEC-HEADER>0001193125-14-359767.hdr.sgml : 20141001
<ACCEPTANCE-DATETIME>20141001061035
ACCESSION NUMBER:		0001193125-14-359767
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20141001
FILED AS OF DATE:		20141001
DATE AS OF CHANGE:		20141001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		141131142

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d798263d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 01 October 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(NASDAQ: NVGN)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g798263tx_pg003.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1&nbsp;October 2014 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA PROVIDES GUIDANCE ON THE CLINICAL
DEVELOPMENT OF CANTRIXIL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY (October 1, 2014) &#150; </B>Novogen Ltd (ASX: NRT; NASDAQ: NVGN) and its subsidiary company, CanTx Inc, have
received guidance from the US Food and Drug Administration (FDA) on the process underway to bring the experimental drug product, Cantrixil, into the clinic in the US for the treatment of late-stage ovarian cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The guidance relates to the drug manufacturing scale-up process, the pre-clinical animal testing program, and the general design of the Phase 1 study in
achieving Investigational New Drug (IND) status for a first-in-man study in the US. This is advice only, designed to ensure that companies are following generally approved processes. It does not guarantee that an IND will be granted eventually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Novogen CEO and Executive Chairman, said today, &#147;We are very familiar with the IND application process and this guidance would not
normally be of any great significance, except for the fact that Cantrixil is a first-in-class product, being developed as an intra-cavity anti-cancer product. What this means is that it has been designed to be delivered directly into cavities such
as the peritoneal cavity (abdomen) and the pleural cavity (thorax). That first-in-class status had the potential to have raised issues by the regulator. Fortunately, no such issues were flagged.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1 clinical trial will be conducted in women with late stage ovarian cancer. Cantrixil will be injected directly into the peritoneal cavity, which is
where ovarian cancer spreads once it leaves the ovary. The drug candidate in Cantrixil, TRX-E-002-1, has been selected for its potent ability to kill ovarian cancer stem cells, the cells believed responsible for spreading the cancer throughout the
abdomen. The rationale is that by injecting Cantrixil directly into the peritoneal cavity, the cancer stem cells and their daughter cells are exposed to much higher levels of the drug candidate than would be achieved by intravenous injection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While this particular IND process is directed at the use of Cantrixil to treat late-stage ovarian cancer, the product has been designed to treat any
form of disseminated cancer within the abdomen. This condition is known as peritoneal carcinomatosis and is a late-stage condition associated mostly with cancers that arise in the abdominal cavity, such as colo-rectal cancer, ovarian cancer and
primary peritoneal cancer. No standard of care exists currently for these conditions, and as far as we know, Cantrixil is the first product to be developed for these conditions, despite their prevalence&#148;, Dr Kelly added. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ
(&#145;NVGN&#146;). The Novogen Group includes a New Haven CT &#150; based joint venture company, CanTx Inc, with Yale University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main
drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament
component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell&#146;s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate
cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CanTx </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx Inc is a private biotechnology company
based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is dedicated to the development of anti-cancer drugs for the treatment of ovarian cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our websites <U>www.novogen.com</U> and <U>www.can-tx.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Corporate Contact</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Media Enquiries</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman&nbsp;&amp; CEO</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Operations Manager</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Novogen Group</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Cristyn.Humphreys@novogen.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Graham.Kelly@novogen.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">+61 (0) 2 9472 4111</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+61 (0)&nbsp;2 9472 4100</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investors Enquiries</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman&nbsp;&amp; CEO</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Novogen Group</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Graham.Kelly@novogen.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+61 (0)&nbsp;2 9472 4100</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g798263tx_pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g798263tx_pg003.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00R:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-D)!.#@T0S$T.3`W,3%%-$(W,S5!.$9%-$4P
M-D5"03<B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-D)!.#@T0S`T.3`W
M,3%%-$(W,S5!.$9%-$4P-D5"03<B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IE.&0X,31F,2TU,#9D+30Q-V,M.#(P."TU
M8V0S.&,S-F-F838B('-T4F5F.F1O8W5M96YT240](G5U:60Z,V0P-#(R-&8M
M,F,U."TT,#EB+3EE,6(M.#<X-V,S-V)D.60V(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P-3@P,CPO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#$T,3`P,2!.
M;W9O9V5N(')E8V5I=F5S(&=U:61A;F-E(&9R;VT@1D1!+F1O8W@\+W)D9CIL
M:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M
M`$A0:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X
M0DE-!"4``````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@`6`$``P$1``(1`0,1`?_$`+X``0`!`P4!`0`````````````*!P@)`0($
M!08#"P$!```&`P$```````````````$"`P<("00%!@H0```&`@$#`@0#`PD'
M!0````$"`P0%!@`'"!$2"2$3,2(4%4$6"E%A(W&!L<$R)!<8&9&AT>'Q,R<E
ME=:'6!$``0,"!0("!0<'"0D``````0`"`Q$$(3$2!09!!U$387$B,@B!0E(C
M%!4)D:%B@M(6&)*R,Y/3)#34%['1<L)C<X0EE?_:``P#`0`"$0,1`#\`G\81
M,(K(?(3SFUYX\^-5FY#W^)7MBS*4AJO2=?1\LVA)?8%SGG!B,*[&R3II()L0
M1CV[E\Z<"W7!NS:*G[#"`%'I]^WNSX]MDFYWI^K9@!U<XY-'^T^`!/177[,]
MH^0=ZN<0\*X^?*D?&^268L+VPQL'O.:"VNIY9&T:F^TX&H`)4=8/U:=8'IUX
M'VH!'\/\PD(/^_\`PERUA[T[;TLY*?\`<'["SF;^&/S<CVN1V@=X?9'?YI>I
MHOZK[5\[=*?"7CAW;:#3INTP<+:+N3=,19?R;!2<BW92-I4@$];1"LPV@VZP
MN56Y'**BB29@*;NZ`/*L>\.TW=[':R6[XXWN`+R\$-J:5(TC+/,+J-__``V>
MX&S[%<;K:[W:7-W"QQ;#]F<SS"`2&Z_M#].HT&HM(;6IP!*EH1DE'S4;'S$0
M]:R<5+,6DE&2+%=-RRD(]\@FZ9/6;E$QTG#5TV5*HF<HB4Y#`(#T'+PK6_<6
M\]I<26ETQT=S$]S'M<*.:YI(<TCH0001T*YV%13")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_.W_4)\]@Y:\OE-+4":!_I3
MBLO,4M@JR<>[&VK;;E5-#8UF(*2AD'2$$LS3A&:GJ`?1N5"#VN,QF[M<F9N.
MYMV>V=6TMO>ID9#[W\G!OK!\5O@^`;L9/V][>GF>\0Z.3[XUDI#FT?%;T)@C
MQ`(JQQE>/I2Z78QBF`P1]?Y@_F'\<LZ,EL(<:N^1;3D`Y#$,`"4Y1*8!]0$!
M#H("'[\BTEK@X9A4Y8VS1NBD%6.!!!Z@J?S^F\YZFY$<7'G%K8$X9[M_BNTC
MXJ$4?+"=_9]&R"IFU)D4S*&%1VI2')#0;D2]01;)L!./<MU'++MER7[]V,6L
M[JWUK1IJ:DL^:?D]T^H>*T&?'AV.D[;]Q1S7:HM/&]\>2_2*-CO`*O&&7GL'
MFBOO2-G(P&$D3+D+`Y,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$5/=M5NV7+5FR*C0[8I0[O:*);*_4+NDT3?JU&S3$$^CX.R
M)LUOX;D\+).$W`$'T,*>4YFO?$YD;M,A:0'>!(P/R'%=SQR^L-LY!8[CNL'V
MG;+>[ADEBK3S(V2-<]GZS06_*OR.ME:[O6H-CW_56S(UY$;(UU<;!4+PQ?G5
M5=IV2$DW#.57.NM_$>)OG"8KI./4'"2I5`$0.`C@_OME=6&[3VM\"+ADC@:^
M-<_ES!ZC%?4QVZY!LW)N&;?O?''LDVVXM8Y(WMI1T;V!S74!--32"1TK3->+
M$2B/4OK^T?WYU&(&*]N2PNJSY5I_1A0/YEGU_3>Z9W!L+R,0NS]=R\A6M>:/
MHMGD=TRZ3?W8VPP=UBWM=K.M7(G$$CO+#80)*)@/4R24(HJ7YB%R\O9W;]R?
MO,FX1$ML(V%LAZ.U#V6^NH#OU5KN_$6Y;Q;;>T@X[N#!+O>X7#&VPZM?&YLC
MY!Z(V`ZCA0R,:<),9M=A\D7!>JV&?JE@Y-:TC;#5IJ2KM@BU7[]1:,FX=VJP
MDXY<[>/60,NR>('3/V',4#%$.N9<P\1Y+<1MFALYG1N`((`Q!%1U\%\Y]YWV
M[0;?=265[R#;X[J*1S'M+S4.8XM<,&T-'`BHJ#F"0NH_U0.`/01_S3:QZ`'4
M?[Y*_#_VO)G\.Y1&*OLIP/4/]ZXW\0?9;+]X]M_EN_95X.OMA4G:]+KNQ=<6
M:)N5(MD>64KEF@W(.HN68F441]]LL`%-_#71.F<A@*=-0AB&`#%$`Z*ZM;FR
MG=;7;'1W#:5:X4(J`1^4$$>@JYVR;YM'(]LBWG8KB*ZVJ;5HEC.ICM+G,=0^
M+7M<UPS#@0<0O99QUVJ81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PBA2?J=N!!ZQ;JAY`]<PX$A+>:%U?R!19)$*DQM"")FFNM@.R$`
M!*G.L$0A'BPAV`X;,>OSKB(V,[P<8;-;LY#:M^L:0V6G4?,=\GNG#Z*VX?AS
M]]1&)NSV^34FC#YK$O.!B<:RPBO6.1VMHS+)'_-BPB.`<G:4"]`[A$>O4/41
MS'DM=6I6W-LL6@-905)/K*W%*LJJDV:H+.WKA9%JS9M4CN'3MVY4*BU:M6Z1
M3JKN7*QRD(0H"8YC```(CE2""2XE;%$"7N-``*E<3<MRM=KLY;RZ>UL<32XD
MD`?E.2GMZ>H3;PJ^)2+B3)M(_EWR-.5_,KE(B$NUVM=X;W`;&4*`KJ16CZ60
M$B^ID/N2)C!VB\'KL![*=O0&V^UO:##"!/<'H7FE&'QK0--,VM<1XKY*OQ1/
MB\N+VZW;DNUW1^L?+MVT:7>XP5\^^8W$`_/8ZE-3K5CJT`,>A!L!"=5#'<KJ
MG46=.7!A5<.G*QS*N'+A4XB=5=PL<QSF$1$QA$1S-Z.$11-8VC6@+Y@KR]GO
M+E]Q,XE[G5S7U]DIO3L(`#\?E#X94H`"203T'I7&\UPQJ:J0#X,>5):U9[9P
M\MTD?[59#R6P]-*O'`^TUF44??OE+9@H82D(^;)A+M4B=H`=)X/01/Z6+[L\
M:>ZWCY%&`)F^S(`,=!/LN-/HN-,>CAC1JV=?`7WA>V\N.UV]S$Q759K/6\D-
MFC;]9$P.-`)HF^8`V@UQ/)!=*2I.66%6TE,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB8148Y$5;2=STALV!Y&P-9LVCU*G)26RH>X-?
MK*\O68),)QVN_0`05$6)HXJZ0I""Q5DR"F/>!<B-N&[.&VF,2B9P;I.1J12M
M<*`XDG`4J<D/.Y>V,4G/HKV3;CM44DYN&5U1M8PZM(`)>7-JP1AKC*7>6&N+
MJ&-BA/\`Z<%9%-1+B7#BF8I3D$VHKV`@4P=0'YIWJ`YZ8?#\XAI^P[=1XJ#0
MXC^K5LY/QB=UB=Y3^1\I!::4%M98'Y)5ZBI;&_3PT*VU:]UGC#!P-EIUAA[+
M7;".F[D[^P3D.^1>Q<W[+J2?(G/%/$B+E$R*O:8@&`HB`96@["SV<@GM[3;6
M2L-014$$8@@^7A^5==N'XN<G);9^S[IR#E,EI<-+'M-O:MJUP+7#5','BK21
M[)K0T"M>\OFW[QM+E^>+L"'T>MJ-0:NZT>1L](^B+?3KU&-+"\V?&.4.K5U^
M:GW]U`Q.HI(QQ$C?.4^7S[9;58V>RCRB?O(R.\ZHH6O:=)C(_P"G2GK)<,'+
M5/\`&QSC?N5=R&6MPTLXU#:1.L2UP?%-:S-$L=TQP`!%SJU5Z!C(S[416,``
M``].OKZ^O[\N<7%Q-<NBPM)).*UZ=<E/3UHNVK%OM6NKC4;_`$1XYC[Y3+-"
M6.FN6A#JKFL$<_14CFA&Z?4[LLBL/TRB(=?>35,00$#=,X6ZVEK?[;/'>`.C
MTD:3UJ*4^4&B]9PG>]WX]R2SWG8Y'Q;C;SLD8YM=37,<'-=3KI(!ID:4(()"
MF@V3RA<2-4/F-%WULUKK?<D96:C([&UZVJU]M@TBR6*MQD\[K3N:K%6F(A=[
M&#(@10A%S*)B``H!3=0#%!G"-^O-5QMD!EV_4[0_4SVF!Q:'9C.E0:4<*.'L
MD%;U_P")+MGL5O;[=SO<8]NY>VU@==VWE7!\B>2&.62+"-U"POTN:7%T;@8W
MTD8\#H?]8;QV_P#Z`#T^/36>W!]/V^E$R!X'RH4!M'>UE[3/VE3_`(K.PU*_
M?L?]1<?V2O!T!R3TIRCI;O8&BKRSO=5CYU[6I!\A'34,ZCYR/1;.',>_B+#&
MQ,NT5^F>I*D,H@4BJ2A3$$Q1ZYT&X[7?[3,(-PC,<A%0#3H:'$5&!&6>1R(5
MU>$]PN']Q=OEW/AU['>VD,OEO+0YI8XM#P'->&N`<UP+74TFC@#5K@*Y9UZ]
MFF$3")A$^'J/PPBVD.10.I#E.`#TZD,!@Z_LZ@(^N$6[")A$PB81;"JI',8I
M%"&,00`Q2G*8Q1$.H`8`$1`1#UPBWX1,(M`,4?@(#_((#A%KA$PB81,(F$3"
M)A$PBCT^<OEB,+5:YQ!I4D`35[(QN6WU6BW16.H;!Y[M=JS@R9NJ:UNFFH.%
MDQZ&^B9`!@['`=UX^U7&'7MY]\73/J!5L9.51@]P_F#UNZ@+7/\`';WECVG9
MXNU6S34OKC1/>EIQ:P4=!`ZF6LTG>,#I;#FR0@QI2I@4I2]``O3H4```#H'I
M_1F1[GDC0['3@%J2+RYQ.90R9#E,0Q0$IRB0Q>@"`E$.@@(?CZ92(#AI=D4:
M]S2'-/M`U"OXC`4Y4<,G5;*122Y`<$&3JPUPX]R\QL#B;/O2C8(1,H$%P]>:
M?FU"N4^IA!&-,4A2B90PY;MS?W<Y8:$1[1N!`+NC9VC#'+ZY@T^)D8W$:J'+
M.WFB[R=E/NUU7<YXC&^2,``NN-I>^LC13VB[;IW"6M0UMK<2T8[RG/98,DH5
M5,BA1[B*%*<AB^H"4P`(#U#T'J`Y<*H<`]KAH.2Q->PL>6.P<#0^M?3N`/40
M-T#]W_+%'G^CHYPZ*2A.`I57F\-Z_6ZB]O\`S$V3'(RNNN*S5C(U"!?`'TNQ
M>15C*JAJ6DHE$Z9GB4.__P#67Y2=XH(-4SJ![9AZ^+Y;=7-\^'C]I6.ZNJ^8
M6YM@`^M?7H:$1M/TWBF(62?8C9[+8FW_`';Y%#')LNQ1M=!')[ESN4E18P4^
M>UKVNNY@,H+9X<"'JT2=L%AN5AL5TN,DM-V^XSLI:+1,.C"=Q)3LT[5?R#I0
M1^`&76$"%#H4A``H````9ZO;[2"PM&VULT-A#0`!D`!0`>@#!6)Y'O\`N/)=
M[N=\W.:2>^N9GR/>\U<YSW%SG$^+G$D^DKJ^TI1Z@4/F'H(]`_X9SBY[(P]E
M*M725)&)R63OQ,<K`XT\G&-.LTG])JC?ZD;2K&+A;VX^OWHBQTZ':5.XQ4FZ
M;AVY/%NE!Z`"3PASCT1#I;#NAQH[OM9W*V8/M,0UB@Q/TF_K#$#Z36CJ5F5\
M&G>)G;KN(W:-YF\OC6[!MO+J/L,?JK!,:Y>7(XM<<A%+(YU=+:3-,Q>6[M0S
MK'<]E<?.='/'G_2YV[SM?XC\W("G[_UZ6>E)"!E>->YX52&LTJQ@%7*K-%[3
M)6/1=IB!`31$$5`*4$CF"7TJGB#7I53%*U98*Y5J!M]7E&DW6K3"QEAK\RP4
M!9E*PLRR1D8R1:*AZ*-WC)P10@_B4P9,JBP<^$O9D-K/Q63FU]DV23-6->[(
MY1W&T3TY)OIAZTK]9O=DEY`XNY)RNX4*W9M3@DF)^T!Z%+TR5N2E!P*I=Q^X
MT[@\P4#_`)MN;>SMM4#C1>Y-X\XX\.-3WB3UY6QUNPDU4(JX;?FJ^9M-VJ>L
MWTHJ%)[B!TR`51)1)(R:01SS0`G/)5,VWX1J5K>#?[+\=.XMX<6>1=7CE7M3
M.VV_=+;KV\.F7<\3JU[A[K*3RR\=,K)D1[Q6.T1$0.JU5#KTA3PS33X*R3D+
MRKV'RJ\>FD>?9(Z3IG*7QI<J:^?D12*\]D(9D=6`FXVJ;08.8QHLN56!LD3(
M1\@9NOWH,NB_]I-$#&9BJA6HKU4I^FVR$OE0JUXK3LDA7;E7(2TP+Y(>J;R&
ML$:VEHQT3J`#VKLG9#>H`/KDRG6&_P`@3F0Y-\\.!W`R#D)=&IUVP/>:?(\D
M)*R$9[NO=4KK16MJQ-+Q:R*PQ5POJRB2J"W\)<J11`0.0O6!Q-%*<314A<R&
M\?,%R*WA1*ENJ_\`'[QV<:KM(:?L<IIB;&M[(Y1[3B?:/;625Y0275A=>0`&
M(3L;]Q5TU4C&(J*XBW9^I,_4JLV?P'<*OLB:NG;!R%T-M"*2%>L;=I.^-ER5
MFB)M-N*3:4=,;%8Y",>)^Z/<LDW*Q.H43$(JD`AT:0A;@O2^,[E'OPVR-_<`
MN9TTA:.1O%=.+FX7;!&XLT]UZ4G#$)7;T_`2)I&F6:3EJ#A<0*HX3=$]XHN4
M7*AP\$!QH<U:O2X3>OFOV/M6]2F\MG<??&_K2^6#5FM*3IB=-3[[R3F*NO\`
M0V:ZVZUI(JNF=/654`K=MV+("0X)%3]TJZV,_4GO>I7#2'@(X-)MFJU#LW*C
M4EK8`!V%_P!;\EMB1=P:N2]/[TB^EG<VR;K'$/F%%ND/K\HE'H(*!-*\SYYX
M\\5PFTA5V\Y:$&3CECQTILA(LK'+1MADX9[^8(1\#V<C7+5^N[>M3B=503?.
MM\XAW`&#DCJT517'@@X$.!4[R\D2@KW=Q$^4^\"%`#?$"]+AU`/Y\4":?6J6
M^8[7-5X^^*BN:HHTC=(NC:WV!Q[I42Y-<[`^N7Y6CK:RC3(O+@\?*SDK(J1X
MB!UW*RAU3]!4[L'`(<E[WQ3[+M6HKKOWQG;BL$E.7OC!*(W?2-FL#U=[*[(X
MP;%<!+U&7(]=B9>1<TZ1DOH'1NX?9!=)$`+[(E*'@C?`KB^3YW(-^</AD29R
MDLP0=<K=A)OFT?*/V#621"D00`WE&K1PBA)-B]X]$URJ$#J/0/4<4J0CEFVR
M*F3")A%`(Y22FTYKE#R#D=Z(BSVM_B99&=D8E,H=E'-6#D6M8CX,ZO4RE;;U
M=-G]O.'4%6HD/U$3"(YB\6;:Q[!:MVFAMQ&VE,?9(K4Y8G$NP'M$U`."^=KO
MY=\HO.ZF\2<J#AO7WA,)6D4TN#RW2T5(T-:&MC()!B#"'.!!-!R]P]HF_?T'
M/6.P]?56?-!4!;LIJ575<$7VS6?,KC^AJ!BVF;;,W#[#,P4EW_8)O6\LS<-]
MF,K0!$7(#7TZ?]4NJ)DE>Q5%,Q2&4`A1\ASHV)XS*;G_``[6$ZQ[S'C%I;^D
M'ANG$8T%:$J__P`-+^4#N[M$7%XFS7DMTV-\;_Z*2%X++ADPQ!A=;&42U#J1
MZG-:7-:JX;'T?XS(39>R8>*YJ;A@XZ+OML8-("`X]R5KK]?2;3;U+[#!6I-P
M1&R1$,8HMF[T@=KA)(#@(@/4?+[9OO/A8Q>7ML+FZ&XNE#2305-",,>G3+HK
MV<I[=_";#R"[B?RZ^B+;F4!D=@^5C0)'!H;*'TD:!0"0`"0`/&#EXXVI/&Z4
MIA_SS[W]`'J(<6Y4PAZ?$`^JSE2\A[@1MU.VR&GZ,P)_,U=`.W_PE$@?OEN?
M_P`V3^T7?<SH^M4?17#C7&C)IY;>*LS6[IL^$V:Z8K0TSM??#J?=0M\>WN!4
M12&O6"DQ*35DSCE.\S=JL;H<_:(EFX=)=7F\7EWO(T;R-#',)KY<.G4P-/4/
M+G/)ZNJ*#2J/Q!,LN/<"XWQSM_*;GMC)%<W$=UI+'W=VZ8PW+IHR*LDMV1P6
M\;"32'2_4[SB5CX#K^/Q_'+ET:,&>ZL.<.F2#Z@(>G7\,F977C[B#.O1<-^"
M(,5C*J"@)$S*&6*<4SH&2#W"+$4*)3)J)&*!BF`0$H@`AE&8@M?'<8V=,UR[
M%\[+V-T%2\/&GTXY?+DIX7!"W;9O?$+05KW=&FC=CS&OHA>8%98ZCZ68D*="
MNV.53423,SF++74FK]VB/7VUW!@]!^4N&_*X+.VY#=0V)'D"4X#)KCBYH]#7
M5'HI3&E3]#?8+=N1[YV@V+<^4M(W22R;1Q-7RPM);!.\4P?+"&/.)U5U^SKT
M-Q<>/BAU;:/+KSIZVO,2VGJ;>]_5>I6:&=D*="1@[!3+K&R30X&*/891LY-V
MG#YB&Z&*("`#GG>IJKOC&H51_$??;7I67WUXO-QRKE[L+AO/G?:;F90P@ZV%
MQ8N3Q20US/,SG`#.QJ_UI6#@0$00*J@B'3VS%*'@@\%C0T>2:/\`IK>5I8`'
M(O\`[[R&,H#/O][[23>B!K!U]OYO8""*Y]W\/:[NOIUR'S5#H5)$X0JPR_#3
MBBK7O9^RFXZ:9^V@W$HI%:AKRO%(0.T1Z'(("!P'U`X#U]>N3*89*Z+"BHZG
M`O5,'OC<OGHU%*-07U7M+D7,4`QS%3<1)9^<JUSCK2Y9(@<S8[I@N^9N>H!T
M]$NOP``E&94HIB`KGO!_MB9LO"9#2=_<"CL_AQL2]\:+^U>K!]8W3H$NN:KO
MG?N`4Q&RU9=HH)J'Z>\#0RGH4P9$9(#@O`>,U*6Y(;5\@GD:'ZAR;=VQ9K07
M&YTH50BK?1O']!Q6XB0B`612*BRN-V34='[0()G+0?=*)R=Y@\4'4KLOT_"K
M$_CT9I%4;'L#;?W()*Z%3,D9ZG:#;$D5UPE>P1/]::-5:F#O]10%,0^7I@9(
MW)9NLBIE'*Y(`LKYF]JEI!'OYG2\36WPGC0X+?6_>57<D%,%0$/4[SKT!KU^
M;OZ=OKD.OR*7J:^"N]\$B\(MXM^,Q8;L!1LTV`VGR@;N6+:$]EVXT\+H!,)R
M.%7IQ.(&Z#VG*(!VB&!DH@U"R2;OW-0>/&I+_N[:4D[A]>:RKCVUVZ48Q;^:
M>,H:/`GU*[:)BT',C(+%[P`$D4SG,(^@9%16$_S:[#@-N^/KC+M+6L@@^@MD
M\FN+MVUU)SC!^P;.D+6TFIFGO9F,<(HRC1JH+UN=R@8A%R$[B]`,'3(')2NR
MP5=Y*&\\IBNOM5V\929Q*K]']74^0QB`?H/M`OV2PF$@&Z=>GKTQCZ$H[Q5,
M//.%F+XMU@NBD,I<B;#X]_FQ2ND=IUY2S%LD;]]/!IOS'?IPQY4%1;`L85@0
M$O>(FZX.2.R7*\J%+L^AG?&;RFZBB'#^[<1'477][0D600=["XJWPS6,OD2[
M*3K]4K3G3[[@U$Q3`W]]9<?^R40'#%1.&*ZKR$7:L;+Y7>#+8E)EFT]4+QR-
MM-KK$RS."C:3@I_7-9DXQZD("/0%V;DAA*/J41$!Z"`ACJ%*[)9Y\BITPB81
M1NO.?Q/!$M7YC4R,#^Z?;-?;L2:IFZJ1RZOTU&NSDI>I>Z.>K?:G2@A_VEVO
M7T3,.7N[4<G?#,=DN7^PT%T=?`FKFU]!.H5Z%_0!:R_CP[,1200]V-BBI,]S
M8;[36A?I#8)B*T&MK?(>0!5X@P+G.)CJ@<#@':/RE_KZ_P!.9!N:1[3\'.R6
MJTM+<\RM1,4H"81```!$1ZA\`RGAUR0-)-!FLEFE%5N'?#.Y\I7)`8;]Y8A,
MZ1XT%63`LE4M6MA_\D;59)*%]Q!20.F"35QZ"4Q&9B=4W!NZV>Y31<GY,S8H
MJ_<EF6R3@'!\N/E,-#B!C(X9&@!Q"S-X7#'V3[+7'<64.CYOR7SK';M0`=!9
MM`;?WD=14.>2RTA>*.:7/D95CJK&6V03;(IH@8QP(4"]QA[C&'\3&,(]3&,/
M41$?41'J.7+C8YK!%1HC9@WU+#FXGDN)G3/]]QJ5]^A?P#_;_P!1RIBT&@:7
M*ACU5]/%`6V]]=[.X)6%VT;2UY7<[DXN2\DJ1)"N[^J,8JO+4Q!PLHF1I'[;
MJK95F<@F`GU:0'*453AU\#R.&7:;N'E307"+ZJYT]87.P<<,3"\A_P#P&098
MC*7LW=-[D<3O^RNXO:;RX)O-J<\5++^&,ZH&DN`:W<+9KK;'`7#;5PJX:7V+
M`1T@==I(,W$=),7+AA)1SQ(R#R/D62QVSYB[04`IT7+1RD9-0A@`2F*(#GM[
M>07,(FCH6D5P6,M_9S6%W):3@MDC<000010]0<0?$'$9'%;NH`/4.G4/7J/[
M,C/C'H!H7%<.E1Z"KW?'7Q95Y<<H*G4)B..ZUA0A;[&VTL8#%:.H"*>)A"5)
M54.@"K<9LB;<Z8""@LDW)P_L"(>+[B<A''ME='"X?:7MTM\=9Z_JBKCTP`.8
M!R;^%GM%_JMW,MK&]8YW'K/^\71I[)BC+:QDG"LSBV$#WM+WO;A&XMG&(HI-
MT4F[=)-!!!,B***1"II(I)%`B:229``A$TR%`"@````'0,Q*<YSG%SB2XFI/
MB5OHBBC@B;#"UK(6-#6M`H``*``#``#``9!82_&/7K-$<Z?,C(S=4M,#%SG)
MR@.J]+3M<FH:)LS,E:M(J/JU)23)JRGV*7O$[UFBBR9>\O40[@ZR@U)4P%"5
MV_D^U==M1;4XX>2_1=2G[3L+CA8D:%O.GTR)?3%BV9QEO[XD;9H\D/%-W3^9
M>TJ2??7-BIHJG2*LHL(=J`"4?%#XKH?#AIZ.M?C*L>G]EU"S,:GL+9')VN2U
M?NE8F*?-2E*NMVL3,'"T)8&3209DDXB0$Z9C)B4!'T$>F!DC<0K=>/G(G>?A
MRCGG$KF'J#;^T^*-,EY0W'/ESJ"DR-_CHK7LG*KO&-0VO!0GOOX%]"*OA*!A
M$5DQ,*:2;E$45"LL\D!(P*K?L'S(K;QAWVM?&GQUWSR/WE9&PQ,);[)JJS:T
MTEK)[()BB6R[`M]\:P:94X3O!<&GMII.!+T]X0`2BKX)7P5\/C@X7#P?XY,M
M<V&R)7K;EVL\[M;>NP$B*`E;]K7-5-W873$ZZ23M2'C2I)M&AEBE4531]TQ$
MQ4%,L:440*#'-83N:LEO#@_RR\A4+HS6.T+3'>1CCW3I+5+NC42S6JNP/)"4
ME2ZKL[^:F(EG(1E;7)"33Z647=^T0RRK<#"5%/O++U*E.!HI#_$?C_`\5^,N
MC^/==(G]!JG7-;JKERF!@"3G6K!-:S31O<464]R:L2[IV;N.<0%;IW#TZY,,
ME,,`L-<E`;^\0O)_=VT=?:4V%R)\?')ZWN-I76K:9A1LFR>-NT9`PC8YF,H[
M=1)68ITN)Q,;V`32!N1%,ZB)FI/J(9'T*&7J59IGSN<89^,"+XZZAY5<D=O2
M+42P6IJ5Q_V#"R82A^U)!M9IZQP[*)@8Y-T<$W#M$7Q4>@F[1+\V*A-2J3XW
M^)N\:U=]Z\X.9J$2SY7<JU(EF\U_"O22<%H_3M>32+4-5,WB:J[5[(I)HI*2
M)TSJ$`Z*9>\ROOG.'CU0#J59E!PO)GPN[>VLA0]%;"Y2^.+<EWD=H1<;I^./
M/;3XR6JP.D@L<62GI'5<3=3]OL*F8@)H+((H&%=LL1P19EZD]WU+H^:7EUXP
M<M^(._N/.DZ+RGM6W=LZRF:E6J6CQJV2>10FI$$>Q"55:1SQDW(V%,?=,DJN
M`=/E[L5%$)J*+9Y$*1>8SP]>/V#6UWL5]8]>W7A+)7&FUZDV&?NU?0IU*55L
M:+^KQC%>5:.XM1J9!8BQ$P27$$SB4PAD#DAR5Y*OF^XQ)'.4-#<]%0((AWI<
M.=J]ANWXB7W&B9A`?Y,C7UIJ"M^\N&V$^7WB*)M?3NM=U+,;IMK6+B+I%EU/
M<(/:C1O7MIN*](N)C77VYW9(QN#N+.LFH=+L.T.FL`]ARCD":A'8C!9WY"IP
M-XUT\H]OB&\Q6;935JO9H.12$S:2A9N%-%R\8\1.`#[3IFY43.`]!`!'X#DR
MF426D:RW5HWF)P6X+W"D;7M%6X;<Y[19]';5)2+1+4R5XQ[9JAYBLHR=Q:1K
MB!8.Z/)-56C@JC@"I&.=,>P$2@,HP-%3.="IA^3*HF$3"+Q&RM=U/;>O[CK&
M]1B<Q3[W792L6&..(%%>-EFJC5<R"O:86SQOW@J@L7YT5B%.7H8H#G*LKR?;
M[N.]MC2:-P</DZ'T$8'Q!*Z#E/&MJYCQV\XOO;/,VN^@=%(,*@.R>VH(#V.`
M>PD'2]K30T6&Q/P'<4DDR)%V;O\`[2$*0!-:ZT8P@4.G4QORE\QARZ[.\6[-
MTZK2!P:*"KY3_P`ZP4?^'IPI[R]W(]VJ23_AK"F/_CK7_0-XG*"0KG9._EV_
M>05V_P";:XD#A$#`*B!E4ZF"B952`)1$H@8`'T'KE23O-NKXW,%C:@D$5U38
M>FFM5[3\/G@]M<QSOY!NTC&/!+3;V`U`&I%1;U%1A48C,+#_`.6:,OE7Y>$U
MW8(-I6-8ZYU=2*QQS@XI1PI!):I9QY6RKMJ=P4G?-*V-LY0D/03D%NB03'("
M:A[@=M';9=[4+QCS)?RN>^<D`'S2:NP&``&D-`PTT(`J0L/_`(R;+D&R]Q(^
M/7MLVTXOM]E#;[;&PN=&+&,$0N#G5+I'N\QTSC[7FZVN+M`<<;8#Z!Z`'3T]
M/Q_?ER?2L.^J#\/3(M]X>%47.A9.TPMBJLQ0E)%+8D;:*Z]H2L04YY<ES0EV
MAZV6-(0#'5>*RWM$(0`'O[NT0$!$,Z_=&0R1S6UQ3[O<T@U]TU&(/HSKZ*KT
M_#KK=['DUG=[(Z5FXQ7#'1F.NL/:X%I93$N#@"VF)<!3%2J]A^&/5&_[6ZW7
M?;OL#56R-D1U?L^S:3K5S5'-&CMCNX-@%U<U\T_6Y.2*VDY\BZYP,L8@JG,8
M@%`W0,:[7N-N>S:K&Q;'-9QDL8Y^NKF-<0PFA;\S2,0":5.)*W![W\%_!NX=
M[^^?)Y;_`&[D6XQ1SW5O;F#RHKF2-CK@,U1R'VI_,>0'N:'/<UAT!J\4/@%T
M"/=_Y\WQ\P=/AKK_`.&9V;>\>^MC\L6UK4=?K*_SUU`_#Z[4BG_L]YP_2M_[
M%9'N%O"+5O"&C62H:]D[%:9&XV,UBM%TN`Q*EDEC(-DV41$G4AHV+9(P\$U*
M<&R)4O11=901$R@YX3D?)]QY/<MN+[2T,!`:VNFI-2[$G$X#U`+)/L]V3X?V
M5VB?:^+B666YE#Y9YM!E<&BC(ZL:T"-IU.#:>\]Q.>%Y>><5X4PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%B/\PO$I?D+QR/L>F1'
MU^V-`C(W."3:)=TC8:2HW(-]JB?8'>Y.I'-22+5,>IA=,0(GZK&`UPNW7(W;
M)O`MI74M+@@>@/!]D^C54M/I+2<JC$'XQ^T7^HW;AV_;9$'<AV4/E%![;[4B
ML[!0'48Z-G:#C1DC6$&0AT/MJX(Z;H.$1`Z:R95"'`?B4P`(#Z?N',K7&-S6
MS-=[+Q5:.YXG03.ADP>TD$>D+[CU_9T`/7TZ_P!>&%O3%W0*D%F3\+/%,-R;
MXD^1-MCOJ-?Z"73:U,CE$#LYW;<FS,=JN3O#L6+1H9?ZLW3U3>NFIOB4<M#W
M4Y._;]K&Q6Y+;JXJ''KY8][^5[@\1K'1;`/@7[0,Y5S"3G>[Q!^S;,YKF!S:
MM?=N%86XX?4C^\.%"6N%N30/%9;68W+<.F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A%M,4IRF(<I3D.42G(8`,4Q3!T,4Q1
MZ@8I@'H(#\<B"0:C`A2N:U[2QX!810@X@@Y@CJ"L,-C\%7#B?LMDL3:T[YK2
M5CGY>?\`R[6[M5&E=@SS#]>04BH!F]H$@[9P[)1P)&Z*BZQDD@*7O'IURXUK
MW1Y+:PMA;Y+@T`5+75RS]\9YGI7*@P6'FZ?`_P!F-TOY;]_WC&99'.T-DATM
M#B2&MK`3I:#I;4EVD#47&I/3_P"@KP_Z"'^(O),.H"'4+[2^OK_]:],KN[L<
MG=TMQZFN_;7`_@0[+?3W3^MA_P`NLHO'#COK?BQJ*L:6U6S?H56LE>J@^FG*
M#^PSTK*/%I"5GK%)-VC%.0EY%VN(G4*BF0I"D33(1,A"%\-O.\WV^WSMPW!V
MJ=P`PR``H`!^<^))/59/]O\`@''.VG&8>*\8C+-NB<YQ+J%\CWFKGO<`T$Y-
M%``UC6M`H`JYYU2]JF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
&)A$PB__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
